The client challenge
Some air-treatment products arrive at the lab as finished devices. Glow Guardian did not. It began as a functional candle concept designed to release active constituents into room air and reduce viable airborne microorganisms under controlled test conditions.1,2
That created an unusual development question. A filter-based purifier draws air through media. A ducted system treats air moving through an HVAC path, while an in-device treatment system acts inside its housing. Glow Guardian was designed as an active-in-air product, releasing constituents into the room where they could interact with airborne microorganisms.1
Glow Guardian needed more than a routine pass/fail test. The development pathway had to connect aerosol science and formulation refinement with bioaerosol generation, viable sampling, chamber testing, and careful interpretation of the resulting data.
ARE Labs as development partner
ARE Labs supported Glow Guardian through formulation work, chamber challenge testing, method adaptation, and final efficacy studies. For each cycle, the team evaluated a candle formulation, measured the bioaerosol response, and used the results to guide the next adjustment. The process was repeated many times as the team worked toward a final product configuration.
The repeated challenges mattered because the performance of an active-in-air product depends on both its mechanism and the fit of the test method. Small changes in formulation, release behavior, burn characteristics, particle behavior, or active delivery can affect the result. In this program, the chamber served as a development feedback tool as well as the setting for final reporting.
How the product was tested
The primary efficacy study tested the Glow Guardian air treatment candle against a broad range of respirable microorganisms in a sealed environmental bioaerosol test chamber. According to the source report, the study followed a protocol modeled on FDA 510(k)-style in-room air purifier testing methods and complied with Good Laboratory Practice expectations in 21 CFR Part 58.3
Each microorganism was aerosolized into a controlled chamber containing the candle. ARE Labs generated the bioaerosol under controlled conditions and collected viable samples over time. The samples were serially diluted, plated, incubated, and enumerated to calculate viable bioaerosol concentrations. Separate control trials measured natural chamber decay, which was subtracted from the candle trials to calculate net reduction.
| Organism or surrogate | Organism type | Maximum net percent reduction | Average CADR |
|---|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 99.74% | 35.40 cfm |
| Phi X bacteriophage | Unenveloped DNA virus surrogate | 99.15% | 24.05 cfm |
| Staphylococcus epidermidis | Gram-positive bacterium | 99.93% | 35.29 cfm |
| Listeria innocua | Gram-positive bacterium | 99.97% | 35.87 cfm |
| Klebsiella aerogenes | Gram-negative bacterium | 99.99% | 46.17 cfm |
| Pseudomonas syringae | Gram-negative bacterium | 99.78% | 47.32 cfm |
| Aspergillus brasiliensis | Mold spores | 81.84% | 12.23 cfm |
| Bacillus subtilis | Bacterial endospores | 34.84% | 3.53 cfm |
Broad-spectrum results
The final broad-range study measured reductions across every organism group tested. For most non-spore organisms, the Glow Guardian candle achieved greater than 99% maximum net percent reduction during the two-hour chamber test period after control correction. More resistant organisms, including mold spores and bacterial endospores, showed lower reductions.
View figure data as a table
| organism | Maximum net reduction |
|---|---|
| MS2 | 99.74% |
| Phi X | 99.15% |
| S. epidermidis | 99.93% |
| L. innocua | 99.97% |
| K. aerogenes | 99.99% |
| P. syringae | 99.78% |
| A. brasiliensis | 81.84% |
| B. subtilis | 34.84% |
Source: client-approved ARE Labs broad-range bioaerosol efficacy report summary.
- Organism names are shortened in the chart labels for readability.
- Values are control-corrected maximum net percent reductions from the source article.
The organism-dependent results added useful context because the biological challenges did not all respond alike. Gram-negative bacteria and virus surrogates showed high reductions, while mold spores and bacterial endospores were more resistant. That pattern is consistent with the greater environmental durability of spores and endospores.
The first-minute question
Because the product was active-in-air, the team also considered what happens when a bioaerosol enters a room that has already been pretreated. With filtration, in-device UV, and many recirculating air cleaners, contaminated air generally must enter the device or treatment zone. When active material is already distributed through the room, the response immediately after aerosol introduction may matter.
ARE Labs tested this scenario in a separate pretreatment study. The candle was lit before the bioaerosol was introduced. After a defined pretreatment period, the organisms were aerosolized into the chamber, and viable concentrations were measured after one minute of chamber mixing.
| Pretreatment challenge organism | Organism type | Net percent reduction after one minute |
|---|---|---|
| MS2 bacteriophage | Unenveloped RNA virus surrogate | 90.66% |
| Klebsiella aerogenes | Gram-negative bacterium | 41.75% |
| Staphylococcus epidermidis | Gram-positive bacterium | 30.80% |
The pretreatment study is summarized here because it shaped the active-in-air method story.
Business impact
Glow Guardian came away with more than a test report. By the end of the program, the client had advanced a functional candle formulation from concept toward product readiness. Glow Guardian also had broad-range viable bioaerosol efficacy data, one-minute room-pretreatment data, and a public-facing account of the science supported by independent laboratory reports.1
That distinction matters to buyers, partners, retailers, and investors. A novel consumer air-treatment product needs more than a general claim that it works. It needs evidence showing that the product mechanism can be challenged, measured, and repeated, then explained without extending the claims beyond the test data.1
The public patent record identifies U.S. Patent No. 12,467,016 B1, titled Air purification candle and assigned to Glow Guardian. Together, the laboratory work, product-development cycle, and public IP record describe the broader outcome: a novel product moved from concept to a documented technical position.2
What this says about method fit
A standard method was not enough for this program because the test method had to match the product's mechanism. For Glow Guardian, aerosol generation, viable bioaerosol sampling, chamber design, particle behavior, formulation support, and GLP-aligned reporting all had to work together.3
For products that depend on airborne actives, room-scale interaction, or nontraditional release behavior, the testing plan should reflect how the product is intended to work. Relying on the closest familiar test category without accounting for the mechanism can cause useful development signals to be missed or misread.
Summary
Glow Guardian needed a development program, not just final validation. The study program helped the client refine the novel active-in-air product concept, connect formulation iteration with room-scale bioaerosol challenge results, and establish control-corrected efficacy data with careful claim boundaries. ARE Labs' testing and interpretation gave Glow Guardian measured evidence for a public success story.